JP2024508683A - Ｓｂｉアジュバントを含む組成物及びその使用方法 - Google Patents

Ｓｂｉアジュバントを含む組成物及びその使用方法 Download PDF

Info

Publication number
JP2024508683A
JP2024508683A JP2023547793A JP2023547793A JP2024508683A JP 2024508683 A JP2024508683 A JP 2024508683A JP 2023547793 A JP2023547793 A JP 2023547793A JP 2023547793 A JP2023547793 A JP 2023547793A JP 2024508683 A JP2024508683 A JP 2024508683A
Authority
JP
Japan
Prior art keywords
antigen
fusion
fragment
polynucleotide
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023547793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508683A5 (enExample
Inventor
カイル バックマン，
ニクヒル ダール，
ニコライ エロシェンコ，
テイラー ギル，
ケモ ジャメ，
マリアンナ キーブニー，
ジャスティン クイン，
ハンヌ ラジャニエミ，
エバレット ウェブスター，
Original Assignee
ヘリックス ナノテクノロジーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘリックス ナノテクノロジーズ， インコーポレイテッド filed Critical ヘリックス ナノテクノロジーズ， インコーポレイテッド
Publication of JP2024508683A publication Critical patent/JP2024508683A/ja
Publication of JP2024508683A5 publication Critical patent/JP2024508683A5/ja
Priority to JP2024213919A priority Critical patent/JP2025026590A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023547793A 2021-03-04 2022-03-03 Ｓｂｉアジュバントを含む組成物及びその使用方法 Withdrawn JP2024508683A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213919A JP2025026590A (ja) 2021-03-04 2024-12-06 Ｓｂｉアジュバントを含む組成物及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156860P 2021-03-04 2021-03-04
US63/156,860 2021-03-04
PCT/US2022/018610 WO2022187424A1 (en) 2021-03-04 2022-03-03 Compositions including sbi adjuvants and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213919A Division JP2025026590A (ja) 2021-03-04 2024-12-06 Ｓｂｉアジュバントを含む組成物及びその使用方法

Publications (2)

Publication Number Publication Date
JP2024508683A true JP2024508683A (ja) 2024-02-28
JP2024508683A5 JP2024508683A5 (enExample) 2024-03-26

Family

ID=80820175

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547793A Withdrawn JP2024508683A (ja) 2021-03-04 2022-03-03 Ｓｂｉアジュバントを含む組成物及びその使用方法
JP2024213919A Pending JP2025026590A (ja) 2021-03-04 2024-12-06 Ｓｂｉアジュバントを含む組成物及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213919A Pending JP2025026590A (ja) 2021-03-04 2024-12-06 Ｓｂｉアジュバントを含む組成物及びその使用方法

Country Status (11)

Country Link
US (3) US11771758B2 (enExample)
EP (1) EP4301404A1 (enExample)
JP (2) JP2024508683A (enExample)
KR (1) KR20230154048A (enExample)
CN (2) CN116916950A (enExample)
AU (2) AU2022228575C1 (enExample)
BR (1) BR112023017749A2 (enExample)
CA (1) CA3211083A1 (enExample)
IL (2) IL320523A (enExample)
MX (1) MX2023009995A (enExample)
WO (1) WO2022187424A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060631A1 (en) * 2017-09-20 2019-03-28 Helix Nanotechnologies, Inc. EXPRESSION SYSTEMS THAT FACILITATE THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE
WO2022187424A1 (en) 2021-03-04 2022-09-09 Helix Nanotechnologies, Inc. Compositions including sbi adjuvants and methods of use thereof
WO2024152844A1 (zh) * 2023-01-19 2024-07-25 成都威斯克生物医药有限公司 抗SARS-CoV-2奥密克戎突变株及其亚型感染的蛋白及疫苗
US12559515B2 (en) 2023-12-22 2026-02-24 Helix Nanotechnologies Inc Cap compounds and RNAS comprising the same
US20250270299A1 (en) * 2024-01-31 2025-08-28 Helix Nanotechnologies Inc Methods of using compositions comprising sbi domains
WO2025166067A1 (en) 2024-01-31 2025-08-07 Helix Nanotechnologies, Inc. Sars-cov-2 vaccine compositions and methods
WO2026015884A1 (en) 2024-07-11 2026-01-15 Helix Nanotechnologies Inc Compositions comprising ire-1 binding sequences and uses thereof
WO2026084768A1 (en) 2024-10-16 2026-04-23 Helix Nanotechnologies Inc Helper proteins for increased secretion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124181A1 (ja) * 2016-12-27 2018-07-05 国立大学法人東京大学 ｍＲＮＡの機能化方法
WO2020097291A1 (en) * 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
WO2021022008A1 (en) * 2019-07-30 2021-02-04 Verndari, Inc. Virus-like particle vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485904B1 (en) * 1997-06-23 2002-11-26 Pfizer, Inc. DNA encoding a plasminogen activating protein
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2002072792A2 (en) * 2001-03-13 2002-09-19 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
GB0605735D0 (en) * 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
GB0610776D0 (en) 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
GB201016403D0 (en) 2010-09-29 2010-11-10 Bath Ventures Novel interaction between staphylococcus aureus Sbi and C3d protiens
SG11201602012RA (en) * 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
GB201619965D0 (en) 2016-11-25 2017-01-11 Univ Of Bath The Immunogenic compositions comprising sbi protein and uses thereof
KR20230039607A (ko) * 2020-05-06 2023-03-21 징코 바이오웍스, 인크. 변이체 SARS-CoV-2 단백질 및 그의 용도
WO2022187424A1 (en) 2021-03-04 2022-09-09 Helix Nanotechnologies, Inc. Compositions including sbi adjuvants and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124181A1 (ja) * 2016-12-27 2018-07-05 国立大学法人東京大学 ｍＲＮＡの機能化方法
WO2020097291A1 (en) * 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
WO2021022008A1 (en) * 2019-07-30 2021-02-04 Verndari, Inc. Virus-like particle vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALMANSOOR A.: "Development of vaccine conjugates based on Dengue virus using a staphylococcal immune evasion protei", A THESIS SUBMITTED FOR THE DEGREE OF MASTER OF PHILOSOPHY (UNIVERSITY OF BATH)[ONLINE], JPN7024001516, 2017, pages 1 - 66, ISSN: 0005388461 *
FRONTIERS IN IMMUNOLOGY, vol. Vol.9, Article 3139, JPN6024014208, 2019, pages 1 - 17, ISSN: 0005388460 *
NATURE, vol. 586, JPN6024014209, 2020, pages 572 - 577, ISSN: 0005388462 *

Also Published As

Publication number Publication date
US20240082388A1 (en) 2024-03-14
CN116916950A (zh) 2023-10-20
MX2023009995A (es) 2023-11-22
WO2022187424A1 (en) 2022-09-09
CA3211083A1 (en) 2022-09-09
US20260061048A1 (en) 2026-03-05
CN119161490A (zh) 2024-12-20
US11771758B2 (en) 2023-10-03
US12343392B2 (en) 2025-07-01
AU2022228575B2 (en) 2025-04-03
AU2022228575A1 (en) 2023-10-12
IL305333B1 (en) 2025-06-01
NZ804057A (en) 2025-07-25
EP4301404A1 (en) 2024-01-10
IL305333B2 (en) 2025-10-01
US20220362373A1 (en) 2022-11-17
IL320523A (en) 2025-06-01
KR20230154048A (ko) 2023-11-07
AU2022228575C1 (en) 2025-10-09
BR112023017749A2 (pt) 2023-10-03
JP2025026590A (ja) 2025-02-21
AU2025205053A1 (en) 2025-07-24
IL305333A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
AU2022228575C1 (en) Compositions including sbi adjuvants and methods of use thereof
JP2021527077A (ja) 新規構造成分を含有するナノ粒子ワクチン
CN113461787A (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
CN111533812A (zh) 针对sars-cov-2病毒的dna疫苗及其用途
US20250319177A1 (en) Rna compositions for delivery of monkeypox antigens and related methods
TW202330922A (zh) 核糖核酸呼吸道融合病毒(rsv)疫苗之組合物及方法
WO2022090679A1 (en) Coronavirus polypeptide
US20240228549A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
TW202438514A (zh) 鼻病毒mrna疫苗
JP2025097909A (ja) Ｓａｒｓ－ｃｏｖ－２免疫原性組成物
US20250026793A1 (en) Chimeric betacoronavirus spike polypeptides
CA3176902A1 (en) Compositions and methods for treating and preventing coronaviruses
CA3130956A1 (en) Novel vaccine effective to prevent infection by sars-cov variants
US20120107910A1 (en) Recombinant envelope protein of human immunodeficiency virus (hiv) and vaccine containing the same
RU2850338C2 (ru) Композиции, содержащие адъюванты sbi, и способы их применения
EP4132572A1 (en) Recombinant vaccines and methods of use thereof
HK40120523A (en) Compositions including sbi adjuvants and methods of use thereof
US20250270299A1 (en) Methods of using compositions comprising sbi domains
US20260015411A1 (en) Rna compositions targeting hiv
US20260041759A1 (en) COVID19 mRNA Vaccine
WO2026030724A1 (en) Sars-cov-2 vaccine
WO2025217530A1 (en) Hiv-1 immunogens and methods of use
CN119264229A (zh) 基于SARS-CoV-2的不同奥密克戎变异型的S蛋白的疫苗和组合物
WO2021252604A1 (en) Coronavirus disease 2019 (covid-19) combination vaccine
WO2025166067A1 (en) Sars-cov-2 vaccine compositions and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240313

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241206

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250314